Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Valganciclovir

Catalog No: tcsc0950

Available Sizes

Size: 50mg

Size: 100mg

Specifications

CAS No:
175865-60-8

Formula:
$C_{14}H_{22}N_6O_5$

Pathway:
Anti-infection

Target:
CMV

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
354.36

Product Description

Valganciclovir, the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections.

IC50 Value:

Target: CMV

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

in vitro: In cell culture model systems using Caco-2 cells for PEPT1 and SKPT cells for PEPT2, valganciclovir inhibited glycylsarcosine transport mediated by PEPT1 and PEPT2 with K(i) values (inhibition constant) of 1.68+/-0.30 and 0.043+/- 0.005 mM, respectively. The inhibition by valganciclovir was competitive in both cases [1].

in vivo: 37 patients were enrolled; 19 patients received treatment with VGV and 18 patients received treatment with GCV. The VGV was not inferior in efficacy to GCV as pre-emptive therapy, with rates of viral clearance at 28 days of 89.5% and 83%, respectively (P-value for non-inferiority = 0.030). Toxicities were similar between the 2 arms. No patients developed CMV disease [2]. Patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily orvalganciclovir 450 mg orally twice daily. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004) [3].